Combination formulations have become a fixture of repair-focused peptide research, and two of the most requested are KLOW and GLOW. They are closely related but not interchangeable, and understanding the difference matters for study design. This article covers what each contains, what each component contributes, how the two differ in practice, and how to handle a multi-component vial.
What GLOW Contains
GLOW combines three compounds, each with its own research literature and its own proposed mechanism.
GHK-Cu is the copper-binding tripeptide central to collagen and remodeling research. In fibroblast culture it increases synthesis of collagen, elastin, and glycosaminoglycans and modulates the matrix metalloproteinases and their inhibitors that govern how connective tissue is remodeled. It also delivers copper, a cofactor for lysyl oxidase, the enzyme that cross-links collagen fibers. Background in GHK-Cu and Copper Peptides.
BPC-157 is the stable gastric-derived pentadecapeptide that dominates the preclinical repair literature, with proposed mechanisms in nitric oxide signaling, growth-factor receptor expression, and angiogenesis. Background in BPC-157 in the Research Literature.
TB-500 is the thymosin beta-4 fragment studied in cell migration. Its parent molecule’s established role is sequestering actin monomers, which regulates how cells move, and the migration effect is the best-documented in the set. Background in TB-500: Research Background.
Together they cover three stages of repair: remodeling and matrix synthesis (GHK-Cu), vascular and growth-factor signaling (BPC-157), and cell migration (TB-500). That makes GLOW a skin-and-matrix oriented research stack.
What KLOW Adds
KLOW contains the same three compounds plus KPV, the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone. KPV retains alpha-MSH’s anti-inflammatory activity without its pigmentary effect, because it does not activate the MC1R melanin pathway. In preclinical models it reduces NF-κB activation and pro-inflammatory cytokine production, and it has a particular literature in intestinal epithelium, where it is taken up by the peptide transporter PepT1 and studied in colitis models. It is also studied in skin barrier and keratinocyte models.
The addition points the blend toward research questions where inflammatory pathways sit alongside repair. Inflammation is the first phase of tissue repair and its resolution is a prerequisite for the later phases, so adding an anti-inflammatory component addresses the step the other three compounds do not directly target. Gut barrier models are the obvious example in the literature; skin models with an inflammatory component are the other.
Side by Side
| GLOW | KLOW | |
|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500, KPV |
| Repair stages covered | Remodeling, vascular signaling, migration | Same, plus inflammation resolution |
| Typical model systems | Skin, dermal fibroblast, connective tissue | Gut barrier, inflammatory skin, mucosal models |
| Most fragile component | GHK-Cu (copper; chelator-sensitive) | GHK-Cu (same) |
| Identity on COA | Three peaks, three masses | Four peaks, four masses |
Choosing Between Them
The practical distinction: GLOW for skin, collagen, and matrix-focused designs; KLOW when the study design also involves inflammation or barrier endpoints. There is a second consideration that cuts the other way: every added component is an added variable. If a result in a KLOW experiment could plausibly come from KPV alone, the design needs a GLOW arm or a KPV-only arm to tell them apart. Laboratories running single-variable designs can source each component individually from our Tissue Research and Cellular & Mitochondrial Research collections. Peptide Blends Explained goes deeper into when a blend is and is not the right tool.
Reading a Blend’s Certificate of Analysis
A COA for a single peptide shows one main HPLC peak and one mass. A COA for GLOW should show three identified components and for KLOW four, each confirmed by mass spectrometry: GHK about 340 Da (the copper complex shifts this), BPC-157 about 1,419 Da, TB-500 either about 4,963 Da for full-length thymosin beta-4 or under 900 Da for the actin-binding fragment, and KPV about 343 Da. A single “purity” percentage is less meaningful for a mixture; what you want is confirmation that every component is present and that there are no unexpected peaks. See What a COA Tells You.
Handling
A blend must be handled to the standard of its most fragile component. Here that is GHK-Cu, whose copper can be stripped by phosphate buffers and chelating agents such as EDTA, so reconstitute in bacteriostatic water or saline and add any buffer only at the final dilution. Full-length TB-500 contains an oxidation-prone methionine, so protect the solution from air and light. The reconstituted blend should be a clear, faintly blue-violet solution (the GHK-Cu color); refrigerate and use within a few weeks. See Reconstitution Basics and Storing Lyophilized Peptides.
All products discussed are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.



